Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
March 19, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
March 15, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
Three additional patients with Fanconi Anemia treated with briquilimab prior to stem cell transplantAll six patients with Fanconi Anemia treated with briquilimab achieved full donor engraftment and...
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
March 04, 2024 07:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
February 26, 2024 16:30 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
February 23, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
February 07, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
February 06, 2024 08:59 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on developing novel antibody therapies...
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
February 05, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024 08:00 ET
|
Jasper Therapeutics, Inc.
REDWOOD CITY, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on development of briquilimab, a novel antibody therapy...
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
January 05, 2024 08:30 ET
|
Jasper Therapeutics, Inc.
- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively - Patient enrollment in Phase 1b/2a SPOTLIGHT study of briquilimab in CIndU...